Literature DB >> 11106671

Consensus panel endorses range of adjuvant therapies for breast cancer.

C McNeil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11106671     DOI： 10.1093/jnci/92.23.1870

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  1 in total

1.  Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).

Authors:  Charles E Geyer; Hanna Bandos; Priya Rastogi; Samuel A Jacobs; André Robidoux; Louis Fehrenbacher; Patrick J Ward; Jonathan Polikoff; Adam M Brufsky; Louise Provencher; Alexander H G Paterson; John T Hamm; Robert L Carolla; Luis Baez-Diaz; Thomas B Julian; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2022-03-01       Impact factor: 4.624
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.